magnitude: hrqol in patients with mcrpc receiving niraparib and abiraterone
Published 6 months ago • 55 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
5:12
magnitude shows benefit of add-on niraparib for mutated mcrpc | gerhardt attard
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
3:14
treatment with abiraterone acetate without steroids in mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
4:55
18f-fluciclovine pet in mcrpc treated with abiraterone acetate
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
1:40
dr. kelly on efficacy of radium-223 dichloride and niraparib in patients with mcrpc
-
1:22
cabazitaxel improves rpfs in patients with mcrpc
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
0:54
convincing long-term survival with abiraterone in mcrpc
-
2:34
first-line treatments for patients with mhspc and mcrpc
-
1:19
dr. kelly on identifying optimal dose of radium-223 and niraparib in mcrpc
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
1:01
dr. kelly on the rationale for combining radium-223 and niraparib in mcrpc
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
1:38
dr. morgan on olaparib for metastatic castration-resistant prostate cancer